This proposal has two overall, interrelated goals. The first is to deepen our understanding of how synapses are formed, shaped, maintained and eliminated. The second is to elucidate how the integrity of the muscle fiber membrane is maintained, with particular regard to muscular dystrophy. Agrin secreted from the nerve terminal induces the formation of nerve-muscle synapses. The agrin signaling receptor MuSK is essential for this induction. However, agrin does not bind MuSK directly and the mechanisms of MuSK activation and localization are unresolved. In the previous funding period we discovered a novel component of Torpedo electric organ postsynaptic membranes, biglycan. Biochemical studies show that this small leucine-rich repeat proteoglycan (SLRP) binds via distinct domains to a a-dystroglycan, the ectodomain of MuSK and to a-and g- sarcoglycan. Both biglycan and its homolog decorin induce MuSK tyrosine phosphorylation when added to cultured myotubes. Moreover, agrin-induced AChR clustering is greatly reduced on myotubes from biglycan null (biglycan-10) mice. Finally, serum creatine kinase levels are markedly elevated in biglycan-10 mice. Together, these observations point to an important role for biglycan and/or decorin in postsynaptic differentiation, and for biglycan in maintaining the integrity of the muscle cell plasma membrane. In the present proposal we will take a combined molecular, biochemical, cell biological, and genetic approach to elucidate the role of biglycan and decorin in synaptic differentiation and in maintaining muscle cell integrity.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
2R01HD023924-13A1
Application #
6292043
Study Section
Special Emphasis Panel (ZRG1-MDCN-1 (01))
Program Officer
Henken, Deborah B
Project Start
1988-08-01
Project End
2006-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
13
Fiscal Year
2001
Total Cost
$337,601
Indirect Cost
Name
Brown University
Department
Neurosciences
Type
Schools of Medicine
DUNS #
001785542
City
Providence
State
RI
Country
United States
Zip Code
02912
Fallon, Justin R; McNally, Elizabeth M (2018) Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics. Matrix Biol 68-69:616-627
Yilmaz, Atilgan; Kattamuri, Chandramohan; Ozdeslik, Rana N et al. (2016) MuSK is a BMP co-receptor that shapes BMP responses and calcium signaling in muscle cells. Sci Signal 9:ra87
Young, Marian F; Fallon, Justin R (2012) Biglycan: a promising new therapeutic for neuromuscular and musculoskeletal diseases. Curr Opin Genet Dev 22:398-400
Amenta, Alison R; Creely, Hilliary E; Mercado, Mary Lynn T et al. (2012) Biglycan is an extracellular MuSK binding protein important for synapse stability. J Neurosci 32:2324-34
Amenta, Alison R; Yilmaz, Atilgan; Bogdanovich, Sasha et al. (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A 108:762-7
Fallon, Justin R (2011) Calcium channels put synapses in their place. Nat Neurosci 14:536-8
Peat, Rachel A; Gecz, Jozef; Fallon, Justin R et al. (2008) Exclusion of biglycan mutations in a cohort of patients with neuromuscular disorders. Neuromuscul Disord 18:606-9
Mercado, Mary Lynn; Amenta, Alison R; Hagiwara, Hiroki et al. (2006) Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20:1724-6
Campagna, J A; Fallon, J (2006) Lipid rafts are involved in C95 (4,8) agrin fragment-induced acetylcholine receptor clustering. Neuroscience 138:123-32
Rafii, Michael S; Hagiwara, Hiroki; Mercado, Mary Lynn et al. (2006) Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. J Cell Physiol 209:439-47

Showing the most recent 10 out of 29 publications